OBJECTIVES Our objective was to estimate the impact of catheter-based renal denervation plus standard of care (RDN) versus standard of care alone (SoC) on European stage-1 hypertension patients with different cardiovascular risk factor profiles. METHODS We simulated resistant hypertension cohorts with different cardiovascular risk factor profiles (CVRPs) who had stage-1 hypertension despite adequate treatment with SoC. Six different cohorts with permutations of starting ages of 40, 55, or 70 years; and low and high CVRPs based on JNC7 guidelines were modeled.  Interventions were RDN plus SoC with three or more anti-hypertensives including a diuretic at full doses or SoC alone. As observed in a recent prospective uncontrolled pilot study, the impact of a 13 mmHg reduction in systolic blood pressure (SBP) – from a baseline SBP of 151 mmHg – was evaluated. Undiscounted life year (LY) and quality-adjusted life year (QALY) gain was computed using a published life-time Markov simulation model based on multivariate risk equations. RESULTS Across the studied age groups and cardiovascular risk profiles, catheter-based renal denervation was associated with gains in unadjusted (0.51-1.48 LYs) and quality-adjusted life expectancy (0.39-1.20 QALYs). Younger age and higher cardiovascular risk profile led to numerically higher increments. The cohort-specific LY and QALY gains were projected as follows: 1) 40 year old cohorts: low CV risk profile: 0.84 LYs/ 0.78 QALYs; high CV risk profile: 1.48 LYs/ 1.20 QALYs; 2) 55 year old cohorts: low CV risk profile: 0.69 LYs/ 0.60 QALYs ; high CV risk profile: 1.29 LYs/ 0.95 QALYs; 3) 70 year old cohorts: low CV risk profile: 0.51 LYs/ 0.39 QALYs; high CV risk profile: 0.99 LYs/ 0.68 QALYs. CONCLUSIONS RDN, when used to treat moderate treatment-resistant hypertension, is associated with clinically significant increases in life expectancy. These model-based findings need to be confirmed in clinical trials.